BR112019005930A2 - combinações compreendendo um inibidor de ssao/vap-1 e um inibidor de sglt2, e usos das mesmas - Google Patents
combinações compreendendo um inibidor de ssao/vap-1 e um inibidor de sglt2, e usos das mesmasInfo
- Publication number
- BR112019005930A2 BR112019005930A2 BR112019005930A BR112019005930A BR112019005930A2 BR 112019005930 A2 BR112019005930 A2 BR 112019005930A2 BR 112019005930 A BR112019005930 A BR 112019005930A BR 112019005930 A BR112019005930 A BR 112019005930A BR 112019005930 A2 BR112019005930 A2 BR 112019005930A2
- Authority
- BR
- Brazil
- Prior art keywords
- inhibitor
- vap
- disorders
- ssao
- combinations
- Prior art date
Links
- 101000774560 Crotalus atrox Zinc metalloproteinase-disintegrin-like VAP1 Proteins 0.000 title abstract 2
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 230000000979 retarding effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16194572 | 2016-10-19 | ||
| PCT/EP2017/076300 WO2018073154A1 (en) | 2016-10-19 | 2017-10-16 | Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019005930A2 true BR112019005930A2 (pt) | 2019-06-11 |
Family
ID=57178303
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019005930A BR112019005930A2 (pt) | 2016-10-19 | 2017-10-16 | combinações compreendendo um inibidor de ssao/vap-1 e um inibidor de sglt2, e usos das mesmas |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210212968A1 (enExample) |
| EP (1) | EP3528800A1 (enExample) |
| JP (1) | JP2019531320A (enExample) |
| KR (1) | KR20190070956A (enExample) |
| CN (1) | CN109843279A (enExample) |
| AU (1) | AU2017344882A1 (enExample) |
| BR (1) | BR112019005930A2 (enExample) |
| CA (1) | CA3041169A1 (enExample) |
| CL (1) | CL2019000935A1 (enExample) |
| EA (1) | EA201990951A1 (enExample) |
| IL (1) | IL265989A (enExample) |
| MX (1) | MX2019004549A (enExample) |
| PH (1) | PH12019500845A1 (enExample) |
| WO (1) | WO2018073154A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190110736A (ko) | 2018-03-21 | 2019-10-01 | 주식회사유한양행 | 신규의 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물 |
| KR20190110740A (ko) | 2018-03-21 | 2019-10-01 | 주식회사유한양행 | 신규의 아릴 또는 헤테로아릴 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물 |
| AU2019351122A1 (en) | 2018-09-28 | 2021-05-20 | Acucela Inc. | Inhibitors of VAP-1 |
| US12037334B2 (en) | 2018-09-28 | 2024-07-16 | Acucela Inc. | Inhibitors of VAP-1 |
| JP7414230B2 (ja) * | 2018-11-09 | 2024-01-16 | 国立大学法人 琉球大学 | 抗血液悪性腫瘍薬 |
| CN121081472A (zh) | 2018-12-13 | 2025-12-09 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| TW202039486A (zh) | 2018-12-14 | 2020-11-01 | 南韓商柳韓洋行股份有限公司 | 三唑并吡啶-3-酮化物或其鹽及包含彼之醫藥組合物 |
| TWI835945B (zh) * | 2018-12-14 | 2024-03-21 | 南韓商柳韓洋行股份有限公司 | 3,3-二氟烯丙胺化物或其鹽及包含彼的醫藥組合物 |
| CA3154391A1 (en) | 2019-09-12 | 2021-03-18 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| AU2020377093A1 (en) | 2019-10-29 | 2022-05-12 | Eccogene Inc. | SSAO inhibitors and use thereof |
| CN115666577A (zh) * | 2020-03-25 | 2023-01-31 | 拓臻股份有限公司 | 呼吸道病症的治疗 |
| IL298145A (en) * | 2020-05-13 | 2023-01-01 | Terns Pharmaceuticals Inc | Combined treatment of liver disorders |
| CN113893256A (zh) * | 2020-07-06 | 2022-01-07 | 诺未科技（北京）有限公司 | 化合物或其可药用盐、二聚体或三聚体在制备治疗癌症的药物中的应用 |
| IL300853A (en) | 2020-08-25 | 2023-04-01 | Lilly Co Eli | Polymorphs of an ssao inhibitor |
| US20240148767A1 (en) * | 2021-03-04 | 2024-05-09 | The Governors Of The University Of Alberta | The use of empagliflozin for the treatment of ulcerative colitis and crohn's disease |
| TW202327589A (zh) * | 2021-11-11 | 2023-07-16 | 美商拓臻製藥公司 | 肝病之組合療法 |
| US20230181583A1 (en) * | 2021-11-11 | 2023-06-15 | Terns Pharmaceuticals, Inc. | Treating liver disorders with an ssao inhibitor |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100591585B1 (ko) | 1999-08-31 | 2006-06-20 | 깃세이 야쿠힌 고교 가부시키가이샤 | 글루코피라노실옥시피라졸 유도체, 그것을 함유하는 의약조성물 및 그 제조 중간체 |
| PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
| US6515117B2 (en) | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| US7053060B2 (en) | 2000-11-30 | 2006-05-30 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof |
| RU2317302C2 (ru) | 2000-12-28 | 2008-02-20 | Киссеи Фармасьютикал Ко., Лтд. | Производные глюкопиранозилоксипиразола и их применение в лекарственных средствах |
| MXPA04009229A (es) | 2002-03-22 | 2004-11-26 | Kissei Pharmaceutical | Cristales derivados de glucopiranosiloxibencil benceno. |
| DE10231370B4 (de) | 2002-07-11 | 2006-04-06 | Sanofi-Aventis Deutschland Gmbh | Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
| JP4222450B2 (ja) | 2003-03-14 | 2009-02-12 | アステラス製薬株式会社 | Ｃ−グリコシド誘導体又はその塩 |
| RS53365B (sr) | 2003-08-01 | 2014-10-31 | Mitsubishi Tanabe Pharma Corporation | Nova jedinjenja koja imaju inhibitorno dejstvo na transporter glukoze zavisan od natrijuma |
| CN103467423B (zh) | 2004-03-16 | 2016-03-16 | 贝林格尔.英格海姆国际有限公司 | 吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法 |
| TW200637839A (en) | 2005-01-07 | 2006-11-01 | Taisho Pharmaceutical Co Ltd | 1-thio-d-glucitol derivatives |
| TW200637869A (en) | 2005-01-28 | 2006-11-01 | Chugai Pharmaceutical Co Ltd | The spiroketal derivatives and the use as therapeutical agent for diabetes of the same |
| UA91546C2 (uk) | 2005-05-03 | 2010-08-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ |
| US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
| ATE517099T1 (de) | 2006-02-15 | 2011-08-15 | Boehringer Ingelheim Int | Glucopyranosyl-substituierte benzonitril-derivate,pharmazeutische zusammensetzungen mit derartigen verbindungen, ihre verwendung und herstellungsverfahren dafür |
| US7803778B2 (en) | 2006-05-23 | 2010-09-28 | Theracos, Inc. | Glucose transport inhibitors and methods of use |
| US7919598B2 (en) | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
| TWI499414B (zh) | 2006-09-29 | 2015-09-11 | Lexicon Pharmaceuticals Inc | 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法 |
| UY30730A1 (es) | 2006-12-04 | 2008-07-03 | Mitsubishi Tanabe Pharma Corp | Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno |
| WO2008109591A1 (en) | 2007-03-08 | 2008-09-12 | Lexicon Pharmaceuticals, Inc. | Phlorizin analogs as inhibitors of sodium glucose co-transporter 2 |
| PE20090185A1 (es) | 2007-03-22 | 2009-02-28 | Bristol Myers Squibb Co | Formulaciones farmaceuticas que contienen un inhibidor sglt2 |
| UA107175C2 (uk) | 2007-07-26 | 2014-12-10 | Спосіб і сполука, призначені для одержання інгібіторів контранспортера натрій-глюкози 2 типу, варіанти | |
| NO2200606T3 (enExample) | 2007-09-10 | 2018-03-24 | ||
| CA2706465A1 (en) | 2007-11-21 | 2009-05-28 | Pharmaxis Ltd. | Haloallylamine inhibitors of ssao/vap-1 and uses therefor |
| TW201011043A (en) | 2008-06-20 | 2010-03-16 | Chugai Pharmaceutical Co Ltd | Crystal of spiroketal derivatives and process for preparation of spiroketal derivatives |
| TWI472521B (zh) | 2008-07-17 | 2015-02-11 | Lexicon Pharmaceuticals Inc | （２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）－２－（４－氯－３－（４－乙氧苄基）苯基）－６－（甲硫）四氫－２ｈ－哌喃－３，４，５－三醇的固體形態與其使用方法 |
| WO2010023594A1 (en) | 2008-08-28 | 2010-03-04 | Pfizer Inc. | Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives |
| SG173032A1 (en) | 2009-02-13 | 2011-08-29 | Boehringer Ingelheim Int | Pharmaceutical composition comprising glucopyranosyl diphenylmethane derivatives, pharmaceutical dosage form thereof, process for their preparation and uses thereof for improved glycemic control in a patient |
| SG2014012462A (en) | 2009-04-16 | 2014-05-29 | Taisho Pharmaceutical Co Ltd | Pharmaceutical compositions |
| WO2011039108A2 (en) | 2009-09-30 | 2011-04-07 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives |
| EA020798B1 (ru) | 2009-09-30 | 2015-01-30 | Бёрингер Ингельхайм Интернациональ Гмбх | СПОСОБ ПОЛУЧЕНИЯ КРИСТАЛЛИЧЕСКОЙ ФОРМЫ 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГИДРОФУРАН-3-ИЛОКСИ)БЕНЗИЛ]БЕНЗОЛА |
| PT2844637T (pt) * | 2012-05-02 | 2018-04-17 | Boehringer Ingelheim Int | Inibidores de 3-haloalilamina substituídos de ssao e as suas utilizações |
-
2017
- 2017-10-16 AU AU2017344882A patent/AU2017344882A1/en not_active Abandoned
- 2017-10-16 CN CN201780063937.5A patent/CN109843279A/zh active Pending
- 2017-10-16 CA CA3041169A patent/CA3041169A1/en not_active Abandoned
- 2017-10-16 WO PCT/EP2017/076300 patent/WO2018073154A1/en not_active Ceased
- 2017-10-16 BR BR112019005930A patent/BR112019005930A2/pt not_active IP Right Cessation
- 2017-10-16 JP JP2019520691A patent/JP2019531320A/ja active Pending
- 2017-10-16 KR KR1020197014347A patent/KR20190070956A/ko not_active Withdrawn
- 2017-10-16 EP EP17804068.9A patent/EP3528800A1/en not_active Withdrawn
- 2017-10-16 US US16/341,460 patent/US20210212968A1/en not_active Abandoned
- 2017-10-16 MX MX2019004549A patent/MX2019004549A/es unknown
- 2017-10-16 EA EA201990951A patent/EA201990951A1/ru unknown
-
2019
- 2019-04-08 CL CL2019000935A patent/CL2019000935A1/es unknown
- 2019-04-11 IL IL265989A patent/IL265989A/en unknown
- 2019-04-17 PH PH12019500845A patent/PH12019500845A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017344882A1 (en) | 2019-03-28 |
| MX2019004549A (es) | 2019-06-12 |
| IL265989A (en) | 2019-06-30 |
| CN109843279A (zh) | 2019-06-04 |
| EP3528800A1 (en) | 2019-08-28 |
| JP2019531320A (ja) | 2019-10-31 |
| CL2019000935A1 (es) | 2019-08-09 |
| KR20190070956A (ko) | 2019-06-21 |
| CA3041169A1 (en) | 2018-04-26 |
| EA201990951A1 (ru) | 2019-11-29 |
| WO2018073154A1 (en) | 2018-04-26 |
| PH12019500845A1 (en) | 2019-12-02 |
| US20210212968A1 (en) | 2021-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019005930A2 (pt) | combinações compreendendo um inibidor de ssao/vap-1 e um inibidor de sglt2, e usos das mesmas | |
| BR112017026739A2 (pt) | compostos para uso no tratamento de distúrbios neuromusculares | |
| BR112016014481A2 (pt) | tratamento de câncer utilizando combinações de inibidores de erk e raf | |
| MX2016007351A (es) | Terapia de combinacion para tratar cancer. | |
| MX391720B (es) | Terapia combinada para tratar cáncer. | |
| MX384403B (es) | Terapia de combinación para el tratamiento del cáncer. | |
| BR112017007975A2 (pt) | composições e métodos para o tratamento de disfunção das glândulas meibomianas | |
| BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
| BR112017018964A2 (pt) | uso de plinabulin e métodos para tratar tumor cerebral | |
| EA201890812A1 (ru) | Дополнительная терапия 25-гидроксивитамином d и изделия для этого | |
| BR112015026247A2 (pt) | métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor | |
| BR112016027041A8 (pt) | combinações farmacêuticas para tratamento do câncer | |
| BR112018003232A2 (pt) | terapias de combinação para tratamento de câncer | |
| BR112017009552A8 (pt) | Métodos para alvejar o controle transcricional em regiões de super-realçador | |
| BR112018005905A2 (pt) | ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto? | |
| BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
| MX381440B (es) | Composicion farmaceutica para tratar colitis ulcerativa. | |
| BR112015032029A2 (pt) | uso de uma composição compreendendo óleo de peixe e suco para o tratamento de inflamação | |
| BR112017027897A2 (pt) | usos terapêuticos das formulações de berberina | |
| EA201691656A2 (ru) | Терапевтические способы с применением норибогаина и родственных соединений | |
| MX2016013611A (es) | Uso del compuesto antigeno 4 del linfocito t toxico (ctla4) para lograr la remision libre de farmacos en sujetos con artritis reumatoide (ra) temprana. | |
| BR112017014924A2 (pt) | Tratamento ou prevenção de caquexia induzida por cirurgia e/ou expressão de células supressoras de origem mieloide e citoquinas pró- inflamatórias | |
| WO2015035410A8 (en) | Cancer therapy | |
| BR112017007863A2 (pt) | composição para o tratamento de condições envolvendo dor muscular | |
| BR112017007364A2 (pt) | composição farmacêutica para o uso no tratamento ou prevenção de deficiências de vitaminas e minerais em pacientes que foram submetidos à cirurgia de bypass gástrico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2692 DE 09-08-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |